Lilly Expands Genetic Medicines Portfolio with Beam's Opt-In Rights Acquisition
Eli Lilly is acquiring Beam Therapeutics' opt-in rights to co-develop and co-commercialize Verve Therapeutics' base editing treatments in the cardiovascular disease space. This move is part of Lilly's ongoing efforts to strengthen its research in genetic medicines, following its previous $60 million upfront payment to Verve for a preclinical-stage program targeting lipoprotein(a).
